Senseonics Expands Debt Facility with Hercules Capital

Senseonics Holdings ( (SENS) ) has issued an announcement.

On September 3, 2025, Senseonics Holdings entered into an Amended Loan Agreement with Hercules Capital, expanding their non-dilutive debt facility to $100 million to fund their commercial organization. This agreement includes an initial term loan of $35 million and additional tranches, with the loans maturing on September 3, 2029. Concurrently, Senseonics signed a Memorandum of Understanding with Ascensia Diabetes Care to transition the commercialization and distribution of Eversense 365 back to Senseonics by January 1, 2026. This strategic move aims to unify the Eversense business under Senseonics, potentially accelerating growth and improving operational efficiency. Brian Hansen, Ascensia’s President of CGM, will join Senseonics as Chief Commercial Officer to lead these efforts.

The most recent analyst rating on (SENS) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Spark’s Take on SENS Stock

According to Spark, TipRanks’ AI Analyst, SENS is a Neutral.

Senseonics Holdings’ overall stock score is primarily impacted by its financial instability and bearish technical indicators. While the earnings call provided a positive outlook with growth in new patient starts and revenue, the company’s financial challenges and negative valuation metrics weigh heavily on the score.

To see Spark’s full report on SENS stock, click here.

More about Senseonics Holdings

Senseonics Holdings, Inc. is a medical technology company that develops and manufactures long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Their primary products include the Eversense 365 and Eversense E3 CGM systems, which are designed to transform glucose management for the global diabetes community.

Average Trading Volume: 6,144,955

Technical Sentiment Signal: Sell

Current Market Cap: $369.1M

Find detailed analytics on SENS stock on TipRanks’ Stock Analysis page.